Macro Group Pharmaceuticals (Macro Capital) S.A.E (EGX:MCRO)
Egypt · Delayed Price · Currency is EGP 1.590
+0.020 (1.27%)
At close: Oct 4, 2026
EGX:MCRO Ratios and Metrics
Market cap in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,440 | 650 | 1,323 | 1,682 | 1,870 | - | |
Market Cap Growth | 194.44% | -50.86% | -21.36% | -10.06% | - | - |
Enterprise Value | 5,007 | 817 | 1,475 | 1,815 | 1,944 | - |
Last Close Price | 1.59 | 1.14 | 0.51 | 0.64 | 0.69 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 10.77 | 5.62 | - | - | 10.76 | - |
Forward PE | 22.71 | 10.07 | 10.07 | 10.07 | 10.07 | - |
PS Ratio | 5.54 | 0.73 | 2.54 | 3.20 | 2.56 | - |
PB Ratio | 6.82 | 3.35 | 16.94 | 17.83 | 4.04 | - |
P/TBV Ratio | 7.06 | 3.89 | 25.84 | 25.10 | 4.56 | - |
P/FCF Ratio | 113.26 | 5.49 | - | - | 14.43 | - |
P/OCF Ratio | 65.64 | 4.04 | - | - | 13.86 | - |
PEG Ratio | - | 0.42 | 0.42 | 0.42 | 0.42 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.10 | 0.91 | 2.84 | 3.45 | 2.66 | - |
EV/EBITDA Ratio | 29.89 | 5.82 | 88.83 | - | 8.17 | - |
EV/EBIT Ratio | 33.73 | 6.03 | 122.57 | - | 8.30 | - |
EV/FCF Ratio | 104.26 | 6.89 | - | - | 15.00 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.05 | 1.72 | 4.05 | 2.40 | 0.44 | 0.27 |
Debt / EBITDA Ratio | 0.26 | 2.19 | 11.06 | - | 0.83 | 0.47 |
Debt / FCF Ratio | 0.90 | 2.81 | - | - | 1.58 | 2.20 |
Net Debt / Equity Ratio | -0.54 | 0.81 | 3.25 | 1.60 | 0.04 | 0.10 |
Net Debt / EBITDA Ratio | -2.78 | 1.12 | 15.30 | -0.86 | 0.08 | 0.18 |
Net Debt / FCF Ratio | -9.01 | 1.33 | -2.93 | -3.39 | 0.14 | 0.84 |
Asset Turnover | 1.04 | 1.29 | 0.92 | 0.77 | 1.02 | 1.21 |
Inventory Turnover | 2.47 | 2.81 | 1.61 | 1.64 | 1.64 | 2.15 |
Quick Ratio | 2.57 | 0.47 | 0.36 | 0.29 | 1.18 | 1.19 |
Current Ratio | 2.97 | 1.35 | 1.35 | 1.08 | 2.00 | 2.31 |
Return on Equity (ROE) | 28.24% | 85.15% | -44.13% | -97.85% | 42.37% | 48.77% |
Return on Assets (ROA) | 9.83% | 12.16% | 1.33% | -16.72% | 20.53% | 25.81% |
Return on Invested Capital (ROIC) | 36.59% | 37.66% | 4.17% | -50.24% | 40.92% | 47.35% |
Return on Capital Employed (ROCE) | 17.90% | 43.10% | 5.20% | -152.40% | 48.50% | 54.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.33% | 17.80% | -2.88% | -16.21% | 9.29% | - |
FCF Yield | 0.88% | 18.23% | -6.56% | -2.64% | 6.93% | - |
Dividend Yield | 6.71% | - | - | - | 15.40% | - |
Payout Ratio | - | - | - | - | 23.01% | 31.65% |
Buyback Yield / Dilution | -49.10% | - | -1.12% | 1.46% | 0.88% | - |
Total Shareholder Return | -42.39% | - | -1.12% | 1.46% | 16.29% | - |